In addition, non-invasive imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), have become increasingly valuable tools for tracking TGF-β signaling changes in pre-clinical animal models, offering crucial data on treatment efficacy and tumor behavior [137–141]. This evidence concerns the gene TGFB1 and neoplasm.